| NA, NA |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
| Recruiting | 3 | 624 | Europe, US, RoW | D-PLEX, Standard of Care (SoC) | PolyPid Ltd. | Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection | 03/25 | 03/25 | | |
STAMINA-01, NCT05205109: A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 98 | RoW | ATG-037, KEYTRUDA ®( Pembrolizumab), MK-3475 | Antengene Therapeutics Limited, Merck Sharp & Dohme LLC | Locally Advanced or Metastatic Solid Tumors | 08/27 | 02/28 | | |
SAMISEN-B, NCT05129449: A Clinical Study With the Medical Device PowerSpiral for Endoscopic Retrograde Cholangio-Pancreatography (ERCP) |
|
|
| Terminated | N/A | 89 | Europe | Endoscopic Retrograde Cholangio-Pancreatography (ERCP) | Olympus Europe SE & Co. KG | Cholangiopancreatography, Endoscopic Retrograde | 06/23 | 06/23 | | |
SENIORHEMO, NCT05218772: Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry |
|
|
| Recruiting | N/A | 612 | Europe | Questionnaires | Assistance Publique Hopitaux De Marseille | Moderate or Serious Haemophilia | 06/23 | 12/23 | | |
INLES, NCT05880121: Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus |
|
|
| Recruiting | N/A | 200 | Europe | MRI | IRCCS San Raffaele, Istituto Giannina Gaslini | Systemic Lupus Erythematosus | 10/24 | 04/26 | | |
CODACO, NCT05869838: A Clinical Study on Endoscopic and Histopathological Outcomes of Screening and Surveillance Colonoscopies |
|
|
| Recruiting | N/A | 600 | Europe | Colonoscopy | Olympus Europe SE & Co. KG | Colonic Polyp | 12/24 | 12/24 | | |
PEER, NCT00568997: 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus |
|
|
| Recruiting | N/A | 8000 | US | Pimecrolimus, Elidel | Bausch Health Americas, Inc., Clinical Research Computing Unit (University of Pennsylvania) | Atopic Dermatitis | 12/26 | 12/26 | | |
| Recruiting | N/A | 700 | Europe | ctDNA, eccDNA | Copenhagen University Hospital at Herlev, Aarhus University Hospital, University of Copenhagen, Odense University Hospital | Resectable Pancreatic Cancer | 01/27 | 01/30 | | |
| Tan, Peter |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) |
|
|
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
NCT04735575: A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma |
|
|
| Recruiting | 1/2 | 66 | RoW | EMB-06 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 12/23 | 03/25 | | |
PXS5505-MF-101, NCT04676529: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis |
|
|
| Active, not recruiting | 1/2 | 43 | US, RoW | PXS-5505 | Syntara, Parexel | Myelofibrosis | 08/25 | 08/25 | | |
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 121 | US, RoW | ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D | Ichnos Sciences SA | Relapsed/Refractory Multiple Myeloma | 05/27 | 05/27 | | |
NCT05003141: PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies |
|
|
| Recruiting | 1a/1b | 110 | US, RoW | PSB202 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma | 07/23 | 01/24 | | |
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome |
|
|
| Completed | 1 | 55 | US, RoW | CB-5339, CB-5339 Tosylate | Cleave Therapeutics, Inc. | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | 07/23 | 07/23 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
WUN101-01, NCT05470140: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) |
|
|
| Active, not recruiting | 1 | 9 | US, RoW | WU-NK-101 | Wugen, Inc. | Acute Myeloid Leukemia | 10/24 | 01/25 | | |
NCT06127628: Effectiveness of Ultrasound-guided Scalp Block for Supratentorial Craniotomy |
|
|
| Recruiting | N/A | 60 | RoW | Ultrasound-guided scalp block with ropivacaine 0.375% | University Malaysia Sarawak | Pain, Postoperative, Anesthesia | 03/25 | 10/25 | | |
